The development of clinical guidelines for the use of zuclopenthixol acetate

Australasian Psychiatry

Volumn 10, Issue 1, 2002, Pages 54-58

  Barnes, Caryl W ^a   Alderton, Deidre ^a   Castle, David ^b  

^a Alma Street Centre ^*  (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical guidelines; Zuclopenthixol acetate

Indexed keywords

ZUCLOPENTHIXOL ACETATE;

AROUSAL; ARTICLE; HUMAN; INTENSIVE CARE UNIT; MEDICAL AUDIT; MENTAL HEALTH SERVICE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT;

EID: 0036195702     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1665.2002.00397.x     Document Type: Article

References (15)

1. Emergency treatment of acute psychosis
2. The role of typical and atypical antipsychotic medication in the management of agitation and aggression
3. Acute psychopharmacological management of the aggressive psychotic patient
4. Psychiatric intensive care in acute psychosis
5. Psychiatric emergencies
6. Evaluating and managing the violent patient
7. Protocols for the use of psychoactive drugs: Part 1: Protocol for the treatment of psychosis with antipsychotics
8. Zuclopenthixol acetate in viscoleo - A new drug preparation
9. Serum concentration and clinical effects of zuclopenthixol in acutely disturbed and psychotic patients treated with zuclopenthixol acetate in viscoleo
10. Long acting anti-psychotic medication, restraint and treatment in the management of acute psychosis
11. Zuclopenthisol acetate in the treatment of acute schizophrenia and similar serious mental illness
12. Zuclopenthixol acetate and haloperidol in acute psychotic patients
13. Acute psychotic disorders treated with 5% zuclopenthixol acetate in viscoleo (cisordinol-acutard). A global assessment of the clinical efficacy. An open multi-center study